Titan Biotech Receives 'Buy' Rating from MarketsMOJO, Showcasing Strong Performance and Growth Potential

Sep 09 2024 06:39 PM IST
share
Share Via
Titan Biotech, a leading chemicals company, has received a 'Buy' rating from MarketsMojo on 2024-09-09. This is due to its high management efficiency with a ROE of 25.97%, low debt to EBITDA ratio of 0.42 times, and consistent positive growth in operating profit, PAT, and net sales. The stock is currently in a bullish trend and has outperformed the market in the long term.
Titan Biotech, a leading player in the chemicals industry, has recently received a 'Buy' rating from MarketsMOJO on 2024-09-09. This upgrade comes as no surprise, considering the company's impressive performance in various aspects.

One of the key reasons for this 'Buy' call is the high management efficiency of Titan Biotech, with a remarkable return on equity (ROE) of 25.97%. This indicates the company's ability to generate profits from its shareholders' investments.

Moreover, Titan Biotech has a strong ability to service its debt, with a low debt to EBITDA ratio of 0.42 times. This showcases the company's financial stability and responsible management.

In terms of growth, Titan Biotech has shown consistent positive results in the last three quarters, with a growth rate of 34.14% in operating profit. The company's PAT (9M) has also seen a significant increase of 29.23%, while its debtors turnover ratio (HY) is at an impressive 8.79 times. Additionally, the net sales (Q) have grown by 24.06%, indicating a healthy long-term growth potential.

From a technical standpoint, the stock is currently in a bullish range and has shown improvement from a mildly bullish trend on 09-Sep-24. Multiple factors, such as MACD, Bollinger Band, and KST, are also indicating a bullish trend for the stock.

With a fair valuation and a price to book value of 3.7, Titan Biotech is trading at a premium compared to its historical valuations. However, this premium is justified by the company's market-beating performance in the long term, with a return of 66.69% in the last year. Additionally, the company has outperformed BSE 500 in the last 3 years, 1 year, and 3 months, further solidifying its position as a strong player in the market.

In conclusion, Titan Biotech's upgraded 'Buy' rating is a testament to its impressive performance and potential for future growth. With a strong management team, healthy financials, and a bullish trend, the company is definitely one to watch out for in the chemicals industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News